The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy
Peritoneal cancer index (PCI) is an important prognostic factor in colorectal cancer peritoneal metastases (CRPM), however it fails to consider the time period over which disease burden develops. The volume-time index (VTI) is the ratio between PCI and time from primary tumour resection. A retrospec...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 2020-01, Vol.219 (1), p.58-64 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 64 |
|---|---|
| container_issue | 1 |
| container_start_page | 58 |
| container_title | The American journal of surgery |
| container_volume | 219 |
| creator | Kozman, Mathew A. Fisher, Oliver M. Valle, Sarah J. Alzahrani, Nayef Liauw, Winston Morris, David L. |
| description | Peritoneal cancer index (PCI) is an important prognostic factor in colorectal cancer peritoneal metastases (CRPM), however it fails to consider the time period over which disease burden develops. The volume-time index (VTI) is the ratio between PCI and time from primary tumour resection.
A retrospective cohort study of 182 patients managed from 1996 to 2017 was performed.
As stratified by high vs low VTI groups, median overall survival (OS) was 23 months (95% 17–46) vs 44 months (95% 35–72) with a difference in 5-year OS of 20.3% (95%CI 10.2–40.4) vs 40.1% (95%CI 29.7–54.1), p = 0.002. No difference in 5-year recurrence free survival (RFS) exists. On multivariable analysis, an elevated VTI was independently associated with poorer OS (adjusted HR 3.20, 95%CI 1.64–6.23, p |
| doi_str_mv | 10.1016/j.amjsurg.2019.03.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2210000361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961019301588</els_id><sourcerecordid>2210000361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-e55da140f8a651332fde865e0094d0df99d8cc998f1aeababc440e74d8eff7cc3</originalsourceid><addsrcrecordid>eNqFkcuKFDEUhoMoTjv6CErAzbioMpe6JCsZBi8DA25atyGdnOpOUZW0Saq138cHNU23Im6EQMjJ__85OR9CLympKaHd27HW85iWuK0ZobImvCaMP0IrKnpZUSH4Y7QihLBKdpRcoWcpjeVIacOfoitOpGBtz1bo53oH-BCmZYYquxmw8xZ-4Juv6_s32CW8j2HrQ8rOlBu819mBzwl_d3mHTZhCBJP1hI32BiLeQ3Q5eCiVGbJOZUHCS4mM2-D8FptjLha7mOwOgE_tQzxi7W1Jz1H_5Tc7mEPeQSken6Mng54SvLjs1-jLh_fru0_Vw-eP93e3D5XhkucK2tZq2pBB6K6lnLPBguhaIEQ2lthBSiuMkVIMVIPe6I1pGgJ9YwUMQ28Mv0Y359zy628LpKxmlwxMk_YQlqQYo2WGhHe0SF__Ix3DEn3pTjHOWtY1PRNF1Z5VJoaUIgxqH92s41FRok4Y1aguGNUJoyJcFYzF9-qSvmxmsH9cv7kVwbuzAMo4Dg6iSqaQMWDdiYiywf3niV-B2bZr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2325264728</pqid></control><display><type>article</type><title>The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Kozman, Mathew A. ; Fisher, Oliver M. ; Valle, Sarah J. ; Alzahrani, Nayef ; Liauw, Winston ; Morris, David L.</creator><creatorcontrib>Kozman, Mathew A. ; Fisher, Oliver M. ; Valle, Sarah J. ; Alzahrani, Nayef ; Liauw, Winston ; Morris, David L.</creatorcontrib><description>Peritoneal cancer index (PCI) is an important prognostic factor in colorectal cancer peritoneal metastases (CRPM), however it fails to consider the time period over which disease burden develops. The volume-time index (VTI) is the ratio between PCI and time from primary tumour resection.
A retrospective cohort study of 182 patients managed from 1996 to 2017 was performed.
As stratified by high vs low VTI groups, median overall survival (OS) was 23 months (95% 17–46) vs 44 months (95% 35–72) with a difference in 5-year OS of 20.3% (95%CI 10.2–40.4) vs 40.1% (95%CI 29.7–54.1), p = 0.002. No difference in 5-year recurrence free survival (RFS) exists. On multivariable analysis, an elevated VTI was independently associated with poorer OS (adjusted HR 3.20, 95%CI 1.64–6.23, p < 0.001) and RFS (adjusted HR 1.90, 95%CI 1.10–3.29, p = 0.02).
VTI is an independent prognostic factor for OS and RFs in patients with CRPM undergoing CRS/IPC, behaving as a surrogate of tumour aggressiveness.
•Volume-time index (VTI) is the ratio of PCI to time from primary tumour resection.•It is an independent prognostic factor in colorectal cancer peritoneal metastases.•Thus, it is a surrogate of underlying tumour aggressiveness.•It provides a useful adjunct for decisions regarding treatment allocation.
Volume-time index (VTI) is the ratio between peritoneal cancer index (PCI) and time from primary tumour resection. It is a surrogate of underlying tumour aggressiveness in patients with colorectal cancer peritoneal metastases (CRPM) undergoing cytoreductive surgery (CRS)/intraperitoneal chemotherapy (IPC).</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2019.03.023</identifier><identifier>PMID: 30982572</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Abdomen ; Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Cancer ; Chemotherapy ; Cohort Studies ; Colorectal cancer ; Colorectal carcinoma ; Colorectal neoplasm ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - therapy ; Cytoreduction Surgical Procedures ; Cytoreductive surgery ; Drug Administration Routes ; Female ; Gastric cancer ; Histology ; Humans ; Intraperitoneal chemotherapy ; Male ; Metastases ; Metastasis ; Middle Aged ; Morbidity ; NMR ; Nuclear magnetic resonance ; Patients ; Peritoneal metastases ; Peritoneal Neoplasms - mortality ; Peritoneal Neoplasms - pathology ; Peritoneal Neoplasms - secondary ; Peritoneal Neoplasms - therapy ; Peritoneum ; Prognosis ; Regression analysis ; Retrospective Studies ; Surgery ; Survival ; Survival Rate ; Time Factors ; Tumor Burden ; Tumors ; Variables ; Variance analysis</subject><ispartof>The American journal of surgery, 2020-01, Vol.219 (1), p.58-64</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><rights>2019. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-e55da140f8a651332fde865e0094d0df99d8cc998f1aeababc440e74d8eff7cc3</citedby><cites>FETCH-LOGICAL-c393t-e55da140f8a651332fde865e0094d0df99d8cc998f1aeababc440e74d8eff7cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2325264728?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30982572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kozman, Mathew A.</creatorcontrib><creatorcontrib>Fisher, Oliver M.</creatorcontrib><creatorcontrib>Valle, Sarah J.</creatorcontrib><creatorcontrib>Alzahrani, Nayef</creatorcontrib><creatorcontrib>Liauw, Winston</creatorcontrib><creatorcontrib>Morris, David L.</creatorcontrib><title>The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Peritoneal cancer index (PCI) is an important prognostic factor in colorectal cancer peritoneal metastases (CRPM), however it fails to consider the time period over which disease burden develops. The volume-time index (VTI) is the ratio between PCI and time from primary tumour resection.
A retrospective cohort study of 182 patients managed from 1996 to 2017 was performed.
As stratified by high vs low VTI groups, median overall survival (OS) was 23 months (95% 17–46) vs 44 months (95% 35–72) with a difference in 5-year OS of 20.3% (95%CI 10.2–40.4) vs 40.1% (95%CI 29.7–54.1), p = 0.002. No difference in 5-year recurrence free survival (RFS) exists. On multivariable analysis, an elevated VTI was independently associated with poorer OS (adjusted HR 3.20, 95%CI 1.64–6.23, p < 0.001) and RFS (adjusted HR 1.90, 95%CI 1.10–3.29, p = 0.02).
VTI is an independent prognostic factor for OS and RFs in patients with CRPM undergoing CRS/IPC, behaving as a surrogate of tumour aggressiveness.
•Volume-time index (VTI) is the ratio of PCI to time from primary tumour resection.•It is an independent prognostic factor in colorectal cancer peritoneal metastases.•Thus, it is a surrogate of underlying tumour aggressiveness.•It provides a useful adjunct for decisions regarding treatment allocation.
Volume-time index (VTI) is the ratio between peritoneal cancer index (PCI) and time from primary tumour resection. It is a surrogate of underlying tumour aggressiveness in patients with colorectal cancer peritoneal metastases (CRPM) undergoing cytoreductive surgery (CRS)/intraperitoneal chemotherapy (IPC).</description><subject>Abdomen</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Cohort Studies</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal neoplasm</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Cytoreduction Surgical Procedures</subject><subject>Cytoreductive surgery</subject><subject>Drug Administration Routes</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Histology</subject><subject>Humans</subject><subject>Intraperitoneal chemotherapy</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Patients</subject><subject>Peritoneal metastases</subject><subject>Peritoneal Neoplasms - mortality</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Peritoneum</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Tumor Burden</subject><subject>Tumors</subject><subject>Variables</subject><subject>Variance analysis</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcuKFDEUhoMoTjv6CErAzbioMpe6JCsZBi8DA25atyGdnOpOUZW0Saq138cHNU23Im6EQMjJ__85OR9CLympKaHd27HW85iWuK0ZobImvCaMP0IrKnpZUSH4Y7QihLBKdpRcoWcpjeVIacOfoitOpGBtz1bo53oH-BCmZYYquxmw8xZ-4Juv6_s32CW8j2HrQ8rOlBu819mBzwl_d3mHTZhCBJP1hI32BiLeQ3Q5eCiVGbJOZUHCS4mM2-D8FptjLha7mOwOgE_tQzxi7W1Jz1H_5Tc7mEPeQSken6Mng54SvLjs1-jLh_fru0_Vw-eP93e3D5XhkucK2tZq2pBB6K6lnLPBguhaIEQ2lthBSiuMkVIMVIPe6I1pGgJ9YwUMQ28Mv0Y359zy628LpKxmlwxMk_YQlqQYo2WGhHe0SF__Ix3DEn3pTjHOWtY1PRNF1Z5VJoaUIgxqH92s41FRok4Y1aguGNUJoyJcFYzF9-qSvmxmsH9cv7kVwbuzAMo4Dg6iSqaQMWDdiYiywf3niV-B2bZr</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Kozman, Mathew A.</creator><creator>Fisher, Oliver M.</creator><creator>Valle, Sarah J.</creator><creator>Alzahrani, Nayef</creator><creator>Liauw, Winston</creator><creator>Morris, David L.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>202001</creationdate><title>The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy</title><author>Kozman, Mathew A. ; Fisher, Oliver M. ; Valle, Sarah J. ; Alzahrani, Nayef ; Liauw, Winston ; Morris, David L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-e55da140f8a651332fde865e0094d0df99d8cc998f1aeababc440e74d8eff7cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Cohort Studies</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal neoplasm</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Cytoreduction Surgical Procedures</topic><topic>Cytoreductive surgery</topic><topic>Drug Administration Routes</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Histology</topic><topic>Humans</topic><topic>Intraperitoneal chemotherapy</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Patients</topic><topic>Peritoneal metastases</topic><topic>Peritoneal Neoplasms - mortality</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Peritoneum</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Tumor Burden</topic><topic>Tumors</topic><topic>Variables</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kozman, Mathew A.</creatorcontrib><creatorcontrib>Fisher, Oliver M.</creatorcontrib><creatorcontrib>Valle, Sarah J.</creatorcontrib><creatorcontrib>Alzahrani, Nayef</creatorcontrib><creatorcontrib>Liauw, Winston</creatorcontrib><creatorcontrib>Morris, David L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kozman, Mathew A.</au><au>Fisher, Oliver M.</au><au>Valle, Sarah J.</au><au>Alzahrani, Nayef</au><au>Liauw, Winston</au><au>Morris, David L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2020-01</date><risdate>2020</risdate><volume>219</volume><issue>1</issue><spage>58</spage><epage>64</epage><pages>58-64</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>Peritoneal cancer index (PCI) is an important prognostic factor in colorectal cancer peritoneal metastases (CRPM), however it fails to consider the time period over which disease burden develops. The volume-time index (VTI) is the ratio between PCI and time from primary tumour resection.
A retrospective cohort study of 182 patients managed from 1996 to 2017 was performed.
As stratified by high vs low VTI groups, median overall survival (OS) was 23 months (95% 17–46) vs 44 months (95% 35–72) with a difference in 5-year OS of 20.3% (95%CI 10.2–40.4) vs 40.1% (95%CI 29.7–54.1), p = 0.002. No difference in 5-year recurrence free survival (RFS) exists. On multivariable analysis, an elevated VTI was independently associated with poorer OS (adjusted HR 3.20, 95%CI 1.64–6.23, p < 0.001) and RFS (adjusted HR 1.90, 95%CI 1.10–3.29, p = 0.02).
VTI is an independent prognostic factor for OS and RFs in patients with CRPM undergoing CRS/IPC, behaving as a surrogate of tumour aggressiveness.
•Volume-time index (VTI) is the ratio of PCI to time from primary tumour resection.•It is an independent prognostic factor in colorectal cancer peritoneal metastases.•Thus, it is a surrogate of underlying tumour aggressiveness.•It provides a useful adjunct for decisions regarding treatment allocation.
Volume-time index (VTI) is the ratio between peritoneal cancer index (PCI) and time from primary tumour resection. It is a surrogate of underlying tumour aggressiveness in patients with colorectal cancer peritoneal metastases (CRPM) undergoing cytoreductive surgery (CRS)/intraperitoneal chemotherapy (IPC).</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30982572</pmid><doi>10.1016/j.amjsurg.2019.03.023</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 2020-01, Vol.219 (1), p.58-64 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2210000361 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Abdomen Adult Aged Antineoplastic Agents - administration & dosage Cancer Chemotherapy Cohort Studies Colorectal cancer Colorectal carcinoma Colorectal neoplasm Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Cytoreduction Surgical Procedures Cytoreductive surgery Drug Administration Routes Female Gastric cancer Histology Humans Intraperitoneal chemotherapy Male Metastases Metastasis Middle Aged Morbidity NMR Nuclear magnetic resonance Patients Peritoneal metastases Peritoneal Neoplasms - mortality Peritoneal Neoplasms - pathology Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Peritoneum Prognosis Regression analysis Retrospective Studies Surgery Survival Survival Rate Time Factors Tumor Burden Tumors Variables Variance analysis |
| title | The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T15%3A28%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20volume-time%20index%20(VTI)%20is%20prognostic%20in%20patients%20with%20colorectal%20cancer%20peritoneal%20metastases%20undergoing%20cytoreductive%20surgery%20and%20intraperitoneal%20chemotherapy&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Kozman,%20Mathew%20A.&rft.date=2020-01&rft.volume=219&rft.issue=1&rft.spage=58&rft.epage=64&rft.pages=58-64&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2019.03.023&rft_dat=%3Cproquest_cross%3E2210000361%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2325264728&rft_id=info:pmid/30982572&rft_els_id=S0002961019301588&rfr_iscdi=true |